$0.40
8.58% today
Nasdaq, Apr 02, 10:19 pm CET
ISIN
US62856X1028
Symbol
TNFA

MyMD Pharmaceuticals Inc Stock price

$0.44
+0.05 12.41% 1M
-1.01 69.52% 6M
-0.71 61.57% YTD
-1.83 80.53% 1Y
-141.16 99.69% 3Y
-121.96 99.64% 5Y
-48,844.36 100.00% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.09 26.26%
ISIN
US62856X1028
Symbol
TNFA
Sector

Key metrics

Market capitalization $1.22m
Enterprise Value $-8.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.89
P/B ratio (TTM) P/B ratio 0.07
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.38m
Free Cash Flow (TTM) Free Cash Flow $-10.14m
Cash position $10.64m
EPS (TTM) EPS $-13.73
Short interest 15.04%
Show more

Is MyMD Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

MyMD Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

Buy
100%

Financial data from MyMD Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.11 6.11
29% 29%
-
- Research and Development Expense 5.27 5.27
29% 29%
-
-11 -11
29% 29%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
29% 29%
-
Net Profit -24 -24
340% 340%
-

In millions USD.

Don't miss a Thing! We will send you all news about MyMD Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MyMD Pharmaceuticals Inc Stock News

Neutral
Business Wire
16 days ago
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session ...
Neutral
Business Wire
28 days ago
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer ...
Neutral
Business Wire
about one month ago
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for c...

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.

Head office United States
CEO Christopher Chapman
Founded 1989
Website tnfpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today